We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+0.58%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.66B
AUM Growth
-$16.4M
Cap. Flow
+$51.9M
Cap. Flow %
3.12%
Top 10 Hldgs %
60%
Holding
84
New
16
Increased
17
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
BOLT icon
Bolt Biotherapeutics
BOLT
+$89.6M
2
NXTC icon
NextCure
NXTC
+$32.2M
3
LLY icon
Eli Lilly
LLY
+$28.1M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$27.3M
5
ALGN icon
Align Technology
ALGN
+$25.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$89.4M
2
ABBV icon
AbbVie
ABBV
+$31.5M
3
AMGN icon
Amgen
AMGN
+$30M
4
UTHR icon
United Therapeutics
UTHR
+$22.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTX icon
51
Immatics
IMTX
$1.13B
$4.32M 0.26%
385,099
+105,567
+38% +$1.2M
ALGS icon
52
Aligos Therapeutics
ALGS
$26.1M
$4.22M 0.25%
7,421
-221
-3% -$147K
APTO
53
DELISTED
Aptose Biosciences, Inc.
APTO
$4.16M 0.25%
1,549
-631
-29% -$1.25M
HRTX icon
54
CALL
Heron Therapeutics
HRTX
$90.8M
$4.05M 0.24%
+250,000
New +$4.46M
BCRX icon
55
BioCryst Pharmaceuticals
BCRX
$2.42B
$3.85M 0.23%
378,774
-744,026
-66% -$7.67M
SVRA icon
56
Savara
SVRA
$1.08B
$3.61M 0.22%
+1,737,450
New +$2.97M
PBYI icon
57
Puma Biotechnology
PBYI
$393M
$3.35M 0.2%
344,917
-284,733
-45% -$3.18M
OTIC
58
DELISTED
Otonomy, Inc.
OTIC
$3.19M 0.19%
1,251,256
-1,369,412
-52% -$5.61M
KURA icon
59
Kura Oncology
KURA
$826M
$2.35M 0.14%
83,164
-37,513
-31% -$1.19M
MGNX icon
60
MacroGenics
MGNX
$240M
$2.33M 0.14%
73,201
-385,606
-84% -$9.36M
SYBX
61
DELISTED
Synlogic
SYBX
$2.06M 0.12%
38,331
– –
CALA
62
DELISTED
Calithera Biosciences, Inc
CALA
$1.83M 0.11%
37,877
+12,861
+51% +$749K
PDSB icon
63
PDS Biotechnology
PDSB
$38.6M
$649K 0.04%
142,635
– –
ABBV icon
64
AbbVie
ABBV
$468B
– –
-293,596
Closed -$31.5M
ACAD icon
65
Acadia Pharmaceuticals
ACAD
$4.39B
– –
-164,625
Closed -$8.8M
ACRS icon
66
Aclaris Therapeutics
ACRS
$733M
– –
-1,911,573
Closed -$12.4M
BCAB icon
67
BioAtla
BCAB
$5.43M
– –
-60
Closed -$102K
BMRN icon
68
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-164,545
Closed -$14.4M
IGMS
69
DELISTED
IGM Biosciences
IGMS
– –
-45,131
Closed -$3.98M
IOVA icon
70
PUT
Iovance Biotherapeutics
IOVA
$2.14B
– –
-100,000
Closed -$4.64M
IWM icon
71
PUT
iShares Russell 2000 ETF
IWM
$80.3B
– –
-130,000
Closed -$25.5M
LQDA icon
72
Liquidia Corp
LQDA
$7.47B
– –
-147,744
Closed -$436K
RCUS icon
73
Arcus Biosciences
RCUS
$3.34B
– –
-186,278
Closed -$4.84M
SRPT icon
74
Sarepta Therapeutics
SRPT
$1.6B
– –
-51,848
Closed -$8.84M
TGTX icon
75
TG Therapeutics
TGTX
$8.52B
– –
-65,474
Closed -$3.41M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2021 Portfolio in Review

As of Q1 2021, Sofinnova Investments held 84 positions worth $1.66B, down 0.98% from $1.68B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments deployed $51.9M of net new capital in Q1 2021, opening 16 new positions and adding to 17 existing holdings. Its largest new stake was Bolt Biotherapeutics: 137,722 shares worth $90.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $89.4M trimmed.

  • Sofinnova Investments's largest Q1 2021 buy was Bolt Biotherapeutics: 137,722 shares worth $90.6M.
  • Sofinnova Investments added most to Eli Lilly in Q1 2021, an estimated $28.1M increase.
  • Sofinnova Investments's biggest Q1 2021 reduction was Ascendis Pharma A/S, cutting an estimated $89.4M.
  • Sofinnova Investments fully exited AbbVie in Q1 2021, selling an estimated $31.5M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.66B portfolio in Q1 2021.
  • Sofinnova Investments opened 16 new positions and closed 20 in Q1 2021.
  • Sofinnova Investments's portfolio value fell 0.98% quarter-over-quarter to $1.66B.

Based on Sofinnova Investments's 13F filing for Q1 2021, filed 14 May 2021.